Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 1 3Phase 2 2Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 20INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Cryosurgery × Clear all
NCT01065441 2020-01-22

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Mirror Biologics, Inc.

Phase 1/2 Completed
9 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02018419 2020-01-22

MBC

Mirror Biologics, Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡